Patent · US Active

Hydroxyalkyl starch for the treatment of hematological neoplasms

US10272102B2 · kind B2 · utility

6Cited by

2References

16Claims

0Family size

Assignee

Fresenius Kabi Deutschland GmbH · DE

Inventors

Martin Westphal · Bad Homburg vor der Höhe, DE
Silke Baasner · Schöneck, DE

Key dates

Filing date	Jul 29, 2014
Grant date	Apr 30, 2019
Priority date	—
Expiry date	Jul 29, 2034

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/02
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to hydroxyalkyl starch or a pharmaceutical preparation thereof for the treatment of a hematological neoplasm, especially by effectively reducing proliferation rate of cancer cells and inhibiting cancer cell growth and wherein the hydroxyalkyl starch has a mean molecular weight (MW) above 20 and below 1300 kDa and a molar substitution (MS) in the range of from 0.1 to 1.5, wherein the alkylation may be an ethylation, propylation or butylation or mixes thereof; and wherein the alkyl may be further substituted.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.